Can AI scans decide who needs surgery after liver cancer combo treatment?
NCT ID NCT07581769
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study looks back at 500 liver cancer patients whose tumors became small enough for surgery after a mix of treatments (TACE, lenvatinib, and an immunotherapy). Researchers want to see if patterns in medical scans and patient data can predict who does better with surgery versus continued medication. The goal is to help doctors choose the best next step for each person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiiated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Conditions
Explore the condition pages connected to this study.